{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-22-000194","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.895018+00:00","generated_at":"2026-06-24T04:35:29.110238+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly Q2 EPS $1.05 ($1.25 non-GAAP); revenue down 4% to $6.49B; key growth products up 20%","bullets":["Revenue $6,488M (-4% YoY; -1% constant currency); core revenue up 6% excluding Alimta, Cialis rights sale, COVID antibodies.","Reported EPS $1.05 (-31%); non-GAAP EPS $1.25 (-32%); both include $0.46 acquired IPR&D charges.","Key growth products (Trulicity, Verzenio, Jardiance etc.) grew 20% to 67% of revenue (ex COVID antibodies).","2022 guidance: reported EPS $6.96-$7.11, non-GAAP $7.90-$8.05; revenue guidance unchanged.","FDA accepted donanemab (Alzheimer's) and pirtobrutinib (MCL) with Priority Review; Mounjaro approved for T2D; Olumiant for alopecia areata."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-22-000194","json":"https://secwatch.observer/filing/0000059478-22-000194.json","markdown":"https://secwatch.observer/filing/0000059478-22-000194.md","text":"https://secwatch.observer/filing/0000059478-22-000194.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000194/0000059478-22-000194-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000194/lly-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:35:29.110238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}